These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4555640)

  • 21. A comparison of typing methods for Serratia marcescens.
    Anderhub B; Pitt TL; Erdman YJ; Willcox WR
    J Hyg (Lond); 1977 Aug; 79(1):89-102. PubMed ID: 328770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of methods for differentiating among Serratia marcescens isolated from clinical specimens.
    Roemisch E; Kocka FE
    Am J Clin Pathol; 1976 Jul; 66(1):96-100. PubMed ID: 779447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined serotyping and biotyping of Serratia marcescens.
    Rubin SJ; Brock S; Chamberland M; Lyons RW
    J Clin Microbiol; 1976 Jun; 3(6):582-5. PubMed ID: 780372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on group A (phage tail) bacteriocins of Serratia marcescens. VI. Calcium ion-dependent biological activity of subgroup II bacteriocins.
    Traub WH; Kleber I
    Zentralbl Bakteriol Orig A; 1976 May; 234(4):528-35. PubMed ID: 779358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiological studies of Serratia marcescens infections by bacteriocin (marcescin) typing.
    Nasu M
    Tohoku J Exp Med; 1981 Jan; 133(1):45-52. PubMed ID: 7015561
    [No Abstract]   [Full Text] [Related]  

  • 26. Automated analysis of 35-S-methionine labeled proteins by SDS-PAGE as a typing method in a suspected cluster of Serratia marcescens.
    Altwegg M; Lüthy-Hottenstein J; Grehn M; von Graevenitz A
    Zentralbl Bakteriol; 1989 Sep; 271(3):372-80. PubMed ID: 2679619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibilities and bacteriological characteristics of bovine Pseudomonas aeruginosa and Serratia marcescens isolates from mastitis.
    Ohnishi M; Sawada T; Hirose K; Sato R; Hayashimoto M; Hata E; Yonezawa C; Kato H
    Vet Microbiol; 2011 Dec; 154(1-2):202-7. PubMed ID: 21783330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic susceptibility of clinical isolates of Serratia marcescens compared with sensitivity to group A (phage tail) bacteriocins.
    Traub WH
    Chemotherapy; 1978; 24(5):301-13. PubMed ID: 352637
    [No Abstract]   [Full Text] [Related]  

  • 29. Epidemiological markers of Serratia marcescens isolates causing nosocomial infections in Spain (1981-1991).
    Boquete T; Vindel A; Martin-Bourgon C; Azañedo L; Sáez-Nieto JA
    Microbiologia; 1996 Dec; 12(4):607-12. PubMed ID: 9018695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The epidemiological type identification of Serratia marcescens from outbreaks of infection in hospitals.
    Pitt TL; Erdman YJ; Bucher C
    J Hyg (Lond); 1980 Apr; 84(2):269-83. PubMed ID: 6987298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epidemiological evaluation of Serratia marcescens clinical isolates in a general hospital during the past three years: appearance of O-antigens O2 and O14].
    Marumo K; Nakamura Y; Sakurai C
    Rinsho Byori; 1998 Jul; 46(7):728-33. PubMed ID: 9721543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Epidemiological evaluation of Serratia marcescens isolates in one Japanese hospital during the two years from April 1997 to March 1999].
    Marumo K; Nakamura Y; Togashi M
    Rinsho Byori; 2000 Oct; 48(10):960-5. PubMed ID: 11215111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotyping of Serratia marcescens: current status of seven recently described flagellar (H) antigens.
    Traub WH; Fukushima PI
    J Clin Microbiol; 1979 Jul; 10(1):56-63. PubMed ID: 387810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nosocomial Serratia marcescens individualized by five typing methods in a regional hospital.
    Larose P; Picard B; Thibault M; Grimont F; Goullet P
    J Hosp Infect; 1990 Feb; 15(2):167-72. PubMed ID: 1969439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [O-serotypes, biochemical properties and antimicrobial susceptibility of Serratia marcescens isolates from clinical specimens].
    Marumo K; Aoki Y; Takeuchi T
    Rinsho Byori; 1987 May; 35(5):555-60. PubMed ID: 2441093
    [No Abstract]   [Full Text] [Related]  

  • 36. Re-evaluation of the serotypes of Serratia marcescens and separation into two schemes based on lipopolysaccharide (O) and capsular polysaccharide (K) antigens.
    Aucken HM; Wilkinson SG; Pitt TL
    Microbiology (Reading); 1998 Mar; 144 ( Pt 3)():639-653. PubMed ID: 9534235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility of Serratia marcescens isolated from clinical materials.
    Igari J; Oguri T; Kosakai N
    Jpn J Antibiot; 1984 Sep; 37(9):1625-30. PubMed ID: 6392599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continued epidemiological surveillance of Serratia marcescens infections by bacteriocin typing, with particular reference to strains isolated at Erlangen.
    Traub WH; Kleber I
    Zentralbl Bakteriol Orig A; 1974; 229(3):372-82. PubMed ID: 4155886
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of MALDI-TOF mass spectrometry to detect nosocomial outbreaks of Serratia marcescens and Citrobacter freundii.
    Rödel J; Mellmann A; Stein C; Alexi M; Kipp F; Edel B; Dawczynski K; Brandt C; Seidel L; Pfister W; Löffler B; Straube E
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):581-591. PubMed ID: 30680577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibacterial Properties of Bacteriocin Purified from Serratia marcescens and Computerized Assessment of its Interaction with Antigen 43 in Escherichia coli.
    Mousavi SM; Archangi B; Zamani I
    Arch Razi Inst; 2023 Dec; 78(6):1738-1745. PubMed ID: 38828162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.